Erasca narrows ERAS-0015 Phase 1 data readout window to mid-May 2026

6 articles · Updated · Simply Wall St · Apr 27

The new timeline accelerates the expected data from the AURORAS-1 and JYP0015M101 trials, previously set for the first half of 2026.
This shift makes ERAS-0015 an even more central near-term catalyst for Erasca, heightening investor focus on upcoming clinical results and the company's risk profile.
Erasca remains unprofitable, with ongoing losses and high dependency on capital markets, making the Phase 1 data pivotal for its valuation and future investment sentiment.

How will the reported patient death affect the FDA's view of Erasca's promising pan-RAS cancer therapy?

Can Erasca's molecular glue outcompete rivals amid a patent lawsuit from Revolution Medicines?

Following the stock's plunge, can strong efficacy data overcome investor fears about the drug's safety profile?

Will a 62% response rate in lung cancer be enough to save Erasca's flagship drug program?

Is severe pneumonitis a manageable side effect or a fatal flaw for this new class of cancer drugs?